Insider Trading Activity Supernus Pharmaceuticals (NASDAQ:SUPN) – VP Sold 60,000 shares of Stock

0

Insider Trading Activity For Supernus Pharmaceuticals (NASDAQ:SUPN)

Victor Vaughn , VP of Supernus Pharmaceuticals (NASDAQ:SUPN) reportedly Sold 60,000 shares of the company’s stock at an average price of 45.33 for a total transaction amount of $2,719,800.00 SEC Form

Insider Trading History For Supernus Pharmaceuticals (NASDAQ:SUPN)

  • On 12/4/2012 John M Siebert, Director, bought 7,000 with an average share price of $8.14 per share and the total transaction amounting to $56,980.00.
  • On 3/14/2013 Gregory S Patrick, CFO, bought 5,000 with an average share price of $6.95 per share and the total transaction amounting to $34,750.00.
  • On 3/15/2013 Jack A Khattar, CEO, bought 10,000 with an average share price of $6.15 per share and the total transaction amounting to $61,500.00.
  • On 3/21/2013 John M Siebert, Director, bought 3,000 with an average share price of $5.50 per share and the total transaction amounting to $16,500.00.
  • On 3/22/2013 Michael Bigham, Director, bought 35,000 with an average share price of $5.41 per share and the total transaction amounting to $189,350.00.
  • On 8/19/2013 Padmanabh Bhatt, VP, sold 2,285 with an average share price of $8.21 per share and the total transaction amounting to $18,759.85.
  • On 3/24/2015 Jones W Bryan, VP, sold 1,900 with an average share price of $12.00 per share and the total transaction amounting to $22,800.00.
  • Analyst Ratings History For Supernus Pharmaceuticals (NASDAQ:SUPN)

    • On 7/18/2016 Northland Securities Downgraded rating Outperform to Market Perform with a price target of $24.00
    • On 9/20/2017 Jefferies Group Reiterated Rating Buy with a price target of $51.00
    • On 9/27/2017 Cantor Fitzgerald Reiterated Rating Buy with a price target of $49.00
    • On 10/19/2017 FBR & Co Initiated Coverage of rating Buy to Buy with a price target of $53.00
    • On 10/23/2017 Cowen Set Price Target of rating Buy with a price target of $50.00
    • On 10/29/2017 Piper Jaffray Set Price Target of rating Hold with a price target of $41.00
    • On 11/3/2017 SunTrust Banks Reiterated Rating Buy with a price target of $61.00

    Recent Trading Activity for Supernus Pharmaceuticals (NASDAQ:SUPN)
    Shares of Supernus Pharmaceuticals closed the previous trading session at 45.60 up +1.50 3.40% with 45.95000076293945 shares trading hands.